CGT Industry Upgrade Series: Shanghai Park Tour Set to Launch
Yeasen
Tool Enzyme Raw Materials and Diagnostic Product R&D, Manufacturer
Saifu Pharmaceutical
Preclinical CRO Service Provider
BIO-LINK
Innovative Products and Solutions Provider
Event Time:November 29, 2023 (Wednesday) 13:30
Event Venue:ATLATL Innovation R&D Center, No. 1077 Zhangheng Road, Pudong New Area, Shanghai
Co-organized by:HIEA, Hangzhou Xingcheng Biotechnology, YeasenYeasen, Saifu Pharmaceutical, Borice, Austar, Legend Capital, ATLATL Innovation Center
Organizer:Arterial New Medicine
Event Duration:Thursday, November 30, 2023, 13:30
Activity SitePoint:No. 215, Fute South Road, Pudong New Area, Shanghai FTZ No. 1 Life Science and Technology Industrial Park
Co-organizers:HIEA, Xingcheng Biotechnology, Yeasen, Saifu Pharmaceutical, Boruice, Austar, Legend CapitalCapital
Organizer:Artery New Medicine
Supporting Organizations:Xingbei · Free Trade No.1, No.1 Entrepreneurs Club
Following the first wave of development, multiple CAR-T products have been submitted for marketing approval in China, and several gene therapy products have entered Phase III clinical trials, continuously expanding into broader disease areas and unlocking significant potential.
Meanwhile, the CGT industry continues to face numerous challenges, such as issues with product quality and batch-to-batch consistency, as well as constraints imposed by high costs and pricing. These factors have made the optimization and iteration of CGT products increasingly urgent. At the same time, the importance of CMC cannot be overlooked; designing superior products, reducing costs while improving efficiency, and developing effective therapeutics are the aspirations of every CGT company. Consequently, service providers across the industry chain and high-quality suppliers have become key drivers of industrial upgrading.
Based on this,Service providers across the CGT industry chain have jointly launched a “Park Tour” initiative, leveraging their respective strengths in equipment, raw materials, consumables, process design, and advanced analytical methods to support innovative enterprises in developing high-quality therapies and driving industrial upgrading in the CGT sector.
High-Net-Worth Attendees:Company founders and department heads and above attended the conference to learn from best practices.
Highly practical content:The invited guests will engage in in-depth discussions on topics including methodologies for cell and gene therapy, lessons learned from common pitfalls, service case studies, and insights into emerging trends.
Precise Matchmaking and Communication:Implement an audit system and extend targeted invitations to guests to ensure the quality of corporate connections in attendance.
This “Shanghai Tour” serves as an initial exploratory initiative. Similar events will be held in other industrial parks in the future to drive the continuous upgrading and development of the CGT industry. We look forward to engaging in discussions and fostering mutual progress with industry peers, thereby empowering the CGT sector to achieve greater heights.
Stop 1: Shanghai · ATLATL Innovation Center
Co-organizers:HIEA, Xingcheng Biotech, YeasenYeasen, Saifu Pharmaceutical, Borice, Austar, Legend Capital, ATLATL Innovation Center
■ 13:30-13:35 Opening Remarks by the Host + Introduction to the Ecosystem
Host | Event Expectations and Ecosystem Synergy Support
■ 13:35–13:40 Address by Park Leadership
Zhangjiang Group
■ Keynote Speech
13：40-14：05
Legend Capital |My Perspective on Investment and Financing in the Cell and Gene Therapy Industry
14：05-14：30
Yeasen |The Key to Scientifically Reducing Costs and Increasing Efficiency in Raw Materials for Cell and Gene Therapy Manufacturing
14：30-14：55
Xingcheng Biotech |Key Points of CMC in Cell and Gene Therapy
14：55-15：20
Saifu Pharmaceutical |Preclinical Research on Cell Therapy Products under the Dual-Track Integration of IIT and IND
■ 15:20–15:30 Tea Break
■ Keynote Speech
15：30-15：55
Borice |Key Explorations Driving the Industrial Upgrade of CGT
15：55-16：20
Austar |Rationalizing Cell Therapy: Domestic Substitution in China
■ 16:20-17:00 Roundtable Discussion
Leveraging CMC Collaboration to Help Innovative Enterprises Achieve a Robust, Rapid, and Cost-Effective Transition from IIT/IND to BLA
■ 17:00-19:00 Dinner Networking
Stop 2: Shanghai · Free Trade No.1
Co-organized by:HIEA, Xingcheng Biotech, Yeasen, Saifu Pharmaceutical, Boruice, Austar, Legend CapitalCapital
Supporting Organizations: Xingbei · Free Trade Zone No.1, No.1 Entrepreneurs Club
■ 13:30–13:35 Host’s Opening Remarks + Ecosystem Introduction
Moderator | Event Expectations and Ecosystem Synergy
■ 13:35-13:40 Address by Park Leadership
Free Trade No.1
■ Keynote Speech
13：40-14：05
Legend Capital |My Perspectives on Investment and Financing in the Cell and Gene Therapy Industry
14：05-14：30
Yeasen |The Secret to Scientifically Reducing Costs and Increasing Efficiency in Raw Materials for Cell and Gene Therapy Manufacturing
14：30-14：55
Xingcheng Biotech |Key Points of CMC in Cell and Gene Therapy
14：55-15：20
Saifu Pharmaceutical |Preclinical Research on Cell Therapy Products under the Integrated Dual-Track System of IIT and IND
■ 15:20-15:30 Tea Break
■ Keynote Speech
15：30-15：55
Borice |Rationalization of Cell Therapy and Domestic Substitution in China
15：55-16：20
Austar |Delivering Technology-Driven Pharmaceutical Engineering Solutions to Enhance Cell Therapy Process Efficiency
■ 16:20-17:00 Roundtable Discussion
Leveraging CMC Collaboration to Help Innovative Enterprises Achieve a Robust, Rapid, and Cost-Effective Transition from IIT/IND to BLA
■ 17:00-19:00 Dinner Reception
Through this series of events, participants will have the opportunity to engage with the latest R&D achievements and technological trends in the industry, expand their professional networks, gain insights into policies and regulations, broaden market channels, and enhance their competitiveness. Meanwhile, these initiatives will further facilitate the upgrading of the cell and gene therapy industry, contributing to human health and well-being.
We warmly welcome practitioners, researchers, investors, and other stakeholders in the cell and gene therapy (CGT) field to participate in this event, jointly exploring and promoting the future development of the CGT industry.
To ensure the quality of the event, a registration review system will be implemented for this activity.
Event Scale: 50 attendees/session
Event Collaboration: Ms. Fu 17851017836 (WeChat ID same as phone number)
Event Registration: Capillary 17782369627 (WeChat ID same as phone number)
